229 related articles for article (PubMed ID: 15284270)
1. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module.
Nowak AK; Stockler MR; Byrne MJ
J Clin Oncol; 2004 Aug; 22(15):3172-80. PubMed ID: 15284270
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire.
Arrieta Ó; Núñez-Valencia C; Reynoso-Erazo L; Alvarado S; Flores-Estrada D; Angulo LP; Oñate-Ocaña LF
Lung Cancer; 2012 Jul; 77(1):205-11. PubMed ID: 22387006
[TBL] [Abstract][Full Text] [Related]
3. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
4. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
Bergman B; Aaronson NK; Ahmedzai S; Kaasa S; Sullivan M
Eur J Cancer; 1994; 30A(5):635-42. PubMed ID: 8080679
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
Arrieta O; López-Macías D; Mendoza-García VO; Bacon-Fonseca L; Muñoz-Montaño W; Macedo-Pérez EO; Muñiz-Hernández S; Blake-Cerda M; Corona-Cruz JF
Cancer Chemother Pharmacol; 2014 May; 73(5):975-82. PubMed ID: 24687408
[TBL] [Abstract][Full Text] [Related]
6. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
Nowak AK; Byrne MJ; Williamson R; Ryan G; Segal A; Fielding D; Mitchell P; Musk AW; Robinson BW
Br J Cancer; 2002 Aug; 87(5):491-6. PubMed ID: 12189542
[TBL] [Abstract][Full Text] [Related]
7. Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13.
Chie WC; Yang CH; Hsu C; Yang PC
Qual Life Res; 2004 Feb; 13(1):257-62. PubMed ID: 15058806
[TBL] [Abstract][Full Text] [Related]
8. Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
Beaumont JL; Lin HM; Goodman E; Yu H; Geiger A; Hudgens S
Value Health; 2024 Feb; 27(2):182-189. PubMed ID: 37951539
[TBL] [Abstract][Full Text] [Related]
9. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
van Meerbeeck JP; Baas P; Debruyne C; Groen HJ; Manegold C; Ardizzoni A; Gridelli C; van Marck EA; Lentz M; Giaccone G
Cancer; 1999 Jun; 85(12):2577-82. PubMed ID: 10375105
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Okuno SH; Delaune R; Sloan JA; Foster NR; Maurer MJ; Aubry MC; Rowland KM; Soori GS; Nikcevich DA; Kardinal CG; Northfelt DW; Adjei AA;
Cancer; 2008 Apr; 112(8):1772-9. PubMed ID: 18224661
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
Byrne MJ; Davidson JA; Musk AW; Dewar J; van Hazel G; Buck M; de Klerk NH; Robinson BW
J Clin Oncol; 1999 Jan; 17(1):25-30. PubMed ID: 10458214
[TBL] [Abstract][Full Text] [Related]
13. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
Eberst G; Anota A; Scherpereel A; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Léna H; Rivière F; Monnet I; Gounant V; Janicot H; Gervais R; Locher C; Charton E; Morin F; Zalcman G; Westeel V;
Clin Cancer Res; 2019 Oct; 25(19):5759-5765. PubMed ID: 31175096
[TBL] [Abstract][Full Text] [Related]
15. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
16. Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer.
Saranya K; Sreejith K; Ajaykumar
J Oncol Pharm Pract; 2019 Dec; 25(8):1853-1859. PubMed ID: 30616471
[TBL] [Abstract][Full Text] [Related]
17. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
Hurt CN; Mukherjee S; Bridgewater J; Falk S; Crosby T; McDonald A; Joseph G; Staffurth J; Abrams RA; Blazeby JM; Bridges S; Dutton P; Griffiths G; Maughan T; Johnson C
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):810-8. PubMed ID: 26530749
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled pilot trial of "Feiji Recipe" on quality of life of non-small cell lung cancer patients.
Tian JH; Liu LS; Shi ZM; Zhou ZY; Wang L
Am J Chin Med; 2010; 38(1):15-25. PubMed ID: 20128041
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
[TBL] [Abstract][Full Text] [Related]
20. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
